Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss of up to 17.8% after 72 weeks. Semaglutide, a weekly GLP-1 ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

20, the FDA announced that the agency has approved Eli Lilly's Zepbound ... in adults with obesity. The drug is to be paired with a reduced-calorie diet and increased physical activity, the ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.